Ken Griffin Deciphera Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Deciphera Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 4,800 shares of DCPH stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,800
Previous 300
1500.0%
Holding current value
$0
Previous $4,000
1775.0%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding DCPH
# of Institutions
178Shares Held
59.6MCall Options Held
5.3KPut Options Held
27.6K-
Black Rock Inc. New York, NY5.99MShares$00.0% of portfolio
-
Armistice Capital, LLC New York, NY5.9MShares$01.26% of portfolio
-
Redmile Group, LLC San Francisco, CA5.3MShares$03.28% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY5.13MShares$01.67% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.57MShares$00.0% of portfolio
About Deciphera Pharmaceuticals, Inc.
- Ticker DCPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,822,100
- Description
- Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...